Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jul 15;98(2):503–512. doi: 10.1172/JCI118818

Requirement and role of C5a in acute lung inflammatory injury in rats.

M S Mulligan 1, E Schmid 1, B Beck-Schimmer 1, G O Till 1, H P Friedl 1, R B Brauer 1, T E Hugli 1, M Miyasaka 1, R L Warner 1, K J Johnson 1, P A Ward 1
PMCID: PMC507456  PMID: 8755663

Abstract

The complement activation product, C5a, may play a key role in the acute inflammatory response. Polyclonal antibody to rat C5a was used to define the requirements for C5a in neutrophil-dependent inflammatory lung injury after systemic activation of complement by cobra venom factor (CVF) or after intrapulmonary deposition of IgG immune complexes. In the CVF model, intravenous infusion (but not intratracheal instillation) of anti-C5a produced a dose-dependent reduction in lung permeability and in lung content of myeloperoxidase. In C6-deficient rats, CVF infusion caused the same level of lung injury (measured by leak of 125I-albumin) as found in C6-sufficient rats. In the IgG immune complex model of lung injury, anti-C5a administered intratracheally (but not intravenously) reduced in a dose-dependent manner both the increase in lung vascular permeability as well as the buildup of lung myeloperoxidase. Treatment with anti-C5a greatly suppressed upregulation of lung vascular intercellular adhesion molecule-1 (ICAM-1). This was correlated with a substantial drop in levels of TNFalpha in bronchoalveolar fluids. These data demonstrate the requirement for C5a in the two models of injury. In the IgG immune complex model, C5a is required for the full production of TNFalpha and the corresponding upregulation of lung vascular ICAM-1.

Full Text

The Full Text of this article is available as a PDF (292.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brauer R. B., Baldwin W. M., 3rd, Daha M. R., Pruitt S. K., Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol. 1993 Dec 15;151(12):7240–7248. [PubMed] [Google Scholar]
  2. Cochrane C. G., Müller-Eberhard H. J., Aikin B. S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol. 1970 Jul;105(1):55–69. [PubMed] [Google Scholar]
  3. Craddock P. R., Fehr J., Dalmasso A. P., Brighan K. L., Jacob H. S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest. 1977 May;59(5):879–888. doi: 10.1172/JCI108710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cui L., Carney D. F., Hugli T. E. Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency. Protein Sci. 1994 Aug;3(8):1169–1177. doi: 10.1002/pro.5560030803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Desai U., Kreutzer D. L., Showell H., Arroyave C. V., Ward P. A. Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol. 1979 Jul;96(1):71–83. [PMC free article] [PubMed] [Google Scholar]
  6. Foreman K. E., Vaporciyan A. A., Bonish B. K., Jones M. L., Johnson K. J., Glovsky M. M., Eddy S. M., Ward P. A. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994 Sep;94(3):1147–1155. doi: 10.1172/JCI117430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Frank M. M., Fries L. F. The role of complement in inflammation and phagocytosis. Immunol Today. 1991 Sep;12(9):322–326. doi: 10.1016/0167-5699(91)90009-I. [DOI] [PubMed] [Google Scholar]
  8. Hangen D. H., Stevens J. H., Satoh P. S., Hall E. W., O'Hanley P. T., Raffin T. A. Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res. 1989 Mar;46(3):195–199. doi: 10.1016/0022-4804(89)90055-3. [DOI] [PubMed] [Google Scholar]
  9. Haslam P. L., Townsend P. J., Branthwaite M. A. Complement activation during cardiopulmonary bypass. Anaesthesia. 1980 Jan;35(1):22–26. doi: 10.1111/j.1365-2044.1980.tb03715.x. [DOI] [PubMed] [Google Scholar]
  10. Hattori R., Hamilton K. K., McEver R. P., Sims P. J. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989 May 25;264(15):9053–9060. [PubMed] [Google Scholar]
  11. Henson P. M., McCarthy K., Larsen G. L., Webster R. O., Giclas P. C., Dreisin R. B., King T. E., Shaw J. O. Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol. 1979 Oct;97(1):93–110. [PMC free article] [PubMed] [Google Scholar]
  12. Hill J. H., Ward P. A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971 Apr 1;133(4):885–900. doi: 10.1084/jem.133.4.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hohn D. C., Meyers A. J., Gherini S. T., Beckmann A., Markison R. E., Churg A. M. Production of acute pulmonary injury by leukocytes and activated complement. Surgery. 1980 Jul;88(1):48–58. [PubMed] [Google Scholar]
  14. Hosea S., Brown E., Hammer C., Frank M. Role of complement activation in a model of adult respiratory distress syndrome. J Clin Invest. 1980 Aug;66(2):375–382. doi: 10.1172/JCI109866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hänsch G. M., Seitz M., Betz M. Effect of the late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int Arch Allergy Appl Immunol. 1987;82(3-4):317–320. doi: 10.1159/000234216. [DOI] [PubMed] [Google Scholar]
  16. Jacob H. S. Complement-induced vascular leukostasis. Its role in tissue injury. Arch Pathol Lab Med. 1980 Dec;104(12):617–620. [PubMed] [Google Scholar]
  17. Johnson A. R., Hugli T. E., Müller-Eberhard H. J. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology. 1975 Jun;28(6):1067–1080. [PMC free article] [PubMed] [Google Scholar]
  18. Johnson K. J., Ward P. A. Acute immunologic pulmonary alveolitis. J Clin Invest. 1974 Aug;54(2):349–357. doi: 10.1172/JCI107770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jones M. L., Warren J. S. Monocyte chemoattractant protein 1 in a rat model of pulmonary granulomatosis. Lab Invest. 1992 Apr;66(4):498–503. [PubMed] [Google Scholar]
  20. Kilgore K. S., Shen J. P., Miller B. F., Ward P. A., Warren J. S. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol. 1995 Aug 1;155(3):1434–1441. [PubMed] [Google Scholar]
  21. Larsen G. L., McCarthy K., Webster R. O., Henson J., Henson P. M. A differential effect of C5a and C5a des Arg in the induction of pulmonary inflammation. Am J Pathol. 1980 Jul;100(1):179–192. [PMC free article] [PubMed] [Google Scholar]
  22. Larsen G. L., Mitchell B. C., Henson P. M. The pulmonary response of C5 sufficient and deficient mice to immune complexes. Am Rev Respir Dis. 1981 Apr;123(4 Pt 1):434–439. doi: 10.1164/arrd.1981.123.4.434. [DOI] [PubMed] [Google Scholar]
  23. Leenaerts P. L., Stad R. K., Hall B. M., Van Damme B. J., Vanrenterghem Y., Daha M. R. Hereditary C6 deficiency in a strain of PVG/c rats. Clin Exp Immunol. 1994 Sep;97(3):478–482. doi: 10.1111/j.1365-2249.1994.tb06113.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McEver R. P., Beckstead J. H., Moore K. L., Marshall-Carlson L., Bainton D. F. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest. 1989 Jul;84(1):92–99. doi: 10.1172/JCI114175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Meuer S., Ecker U., Hadding U., Bitter-Suermann D. Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J Immunol. 1981 Apr;126(4):1506–1509. [PubMed] [Google Scholar]
  26. Mulligan M. S., Polley M. J., Bayer R. J., Nunn M. F., Paulson J. C., Ward P. A. Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest. 1992 Oct;90(4):1600–1607. doi: 10.1172/JCI116029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mulligan M. S., Smith C. W., Anderson D. C., Todd R. F., 3rd, Miyasaka M., Tamatani T., Issekutz T. B., Ward P. A. Role of leukocyte adhesion molecules in complement-induced lung injury. J Immunol. 1993 Mar 15;150(6):2401–2406. [PubMed] [Google Scholar]
  28. Mulligan M. S., Vaporciyan A. A., Miyasaka M., Tamatani T., Ward P. A. Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol. 1993 Jun;142(6):1739–1749. [PMC free article] [PubMed] [Google Scholar]
  29. Mulligan M. S., Wilson G. P., Todd R. F., Smith C. W., Anderson D. C., Varani J., Issekutz T. B., Miyasaka M., Tamatani T., Myasaka M. Role of beta 1, beta 2 integrins and ICAM-1 in lung injury after deposition of IgG and IgA immune complexes. J Immunol. 1993 Mar 15;150(6):2407–2417. [PubMed] [Google Scholar]
  30. Mulligan M. S., Yeh C. G., Rudolph A. R., Ward P. A. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J Immunol. 1992 Mar 1;148(5):1479–1485. [PubMed] [Google Scholar]
  31. Perkowski S. Z., Havill A. M., Flynn J. T., Gee M. H. Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation. Circ Res. 1983 Nov;53(5):574–583. doi: 10.1161/01.res.53.5.574. [DOI] [PubMed] [Google Scholar]
  32. Rinder C. S., Rinder H. M., Smith B. R., Fitch J. C., Smith M. J., Tracey J. B., Matis L. A., Squinto S. P., Rollins S. A. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995 Sep;96(3):1564–1572. doi: 10.1172/JCI118195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Shanley T. P., Schmal H., Friedl H. P., Jones M. L., Ward P. A. Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol. 1995 May 1;154(9):4793–4802. [PubMed] [Google Scholar]
  34. Smedegård G., Cui L. X., Hugli T. E. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol. 1989 Sep;135(3):489–497. [PMC free article] [PubMed] [Google Scholar]
  35. Späth P. J. Role of complement in inflammation and bacterial killing. Curr Stud Hematol Blood Transfus. 1992;(59):100–145. [PubMed] [Google Scholar]
  36. Stevens J. H., O'Hanley P., Shapiro J. M., Mihm F. G., Satoh P. S., Collins J. A., Raffin T. A. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest. 1986 Jun;77(6):1812–1816. doi: 10.1172/JCI112506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Till G. O., Johnson K. J., Kunkel R., Ward P. A. Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest. 1982 May;69(5):1126–1135. doi: 10.1172/JCI110548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Till G. O., Morganroth M. L., Kunkel R., Ward P. A. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat. Am J Pathol. 1987 Oct;129(1):44–53. [PMC free article] [PubMed] [Google Scholar]
  39. Tvedten H. W., Till G. O., Ward P. A. Mediators of lung injury in mice following systemic activation of complement. Am J Pathol. 1985 Apr;119(1):92–100. [PMC free article] [PubMed] [Google Scholar]
  40. Weisman H. F., Bartow T., Leppo M. K., Marsh H. C., Jr, Carson G. R., Concino M. F., Boyle M. P., Roux K. H., Weisfeldt M. L., Fearon D. T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990 Jul 13;249(4965):146–151. doi: 10.1126/science.2371562. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES